Stoke Therapeutics, Inc. STOK EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s EPS (basic)?
- Stoke Therapeutics, Inc. (STOK) reported EPS (basic) of -$0.79 in Q1 2026.
- How has Stoke Therapeutics, Inc.'s EPS (basic) changed year-over-year?
- Stoke Therapeutics, Inc.'s EPS (basic) decreased by 140.5% year-over-year, from $1.95 to -$0.79.
- What is the long-term trend for Stoke Therapeutics, Inc.'s EPS (basic)?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s EPS (basic) has grown at a -54.5% compound annual growth rate (CAGR), from -$2.34 to -$0.10.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.